Agena BIOSCIENCE provides technologies and tools for translational research, oncology, agricultural genomics and clinical diagnostics. Agena BIOSCIENCE's proprietary MassARRAY® System is a high-performance MALDI-TOF mass spectrometry-based DNA analysis platform that delivers reliable and specific data from biological samples and from genetic target material that is only available in trace amounts.
Agena BIOSCIENCE is a manufacturer of DNA massarrays platform and is used for SNP genotyping, methylation detection and quantitative gene expression analysis. Agena BIOSCIENCE offers Genotyping, Somatic mutation profiling, Methylation analysis, Quantitative gene expression, Pathogen identification/molecular typing and clinical molecular genetics testing, such as MaterniT21 PLUS, a noninvasive prenatal test for trisomy 21, trisomy 18, and trisomy 13, RetnaGene AMD a genetic test for risk of progression for age-related macular degeneration, Heredi-T Cystic Fibrosis Screening Test, and the SensiGene Fetal RHD Genotyping Test.
Agena BIOSCIENCE provides best-in-class laboratory testing services with a focus on prenatal and ophthalmological diseases and conditions, including the market-leading MaterniT21™ PLUS noninvasive prenatal laboratory-developed test intended for use in pregnant women at increased risk for fetal aneuploidies.
Key Applications
- Genotyping
- Somatic mutation profiling
- Methylation analysis
- Quantitative gene expression
- Pathogen identification/molecular typing
- Highly accurate, sensitive analysis for cancer research
GENETICS
Identifying and studying genetic factors that contribute to disease requires sophisticated research tools and complex experimental designs. Complex diseases, including cancer, cardiovascular disease, and neurological disorders, are often associated with multiple genetic and epigenetic factors, requiring flexible and customizable analysis tools.
ONCOLOGY
Genetic and somatic mutations can be employed to study their effect on oncogenesis, disease progression, or therapeutic response. Mutations play a key role as biomarkers for risk, progression, and prognosis.
BIOMARKER VALIDATION
Genomic biomarkers with potential clinical utility may be associated with disease state or therapeutic response, and include SNPs, somatic mutations, expressed RNA transcripts, DNA methylation regions, and copy number variations.
PHARMACOGENOMICS
The relationship between a person’s genetic makeup and the way that person responds to and metabolizes drugs - plays an important role in healthcare today. Often referred to as “personalized medicine,” it is based on ascertaining the relevant variance of individuals versus average responses of whole populations.
EPIGENETICS
The related field of epigenetics aims to elucidate the role of specific epigenetic elements in biological processes, such as DNA methylation changes in diseases including cancer.
AGBIO
Agena BIOSCIENCE's MassARRAY® System is a powerful tool for downstream marker validation and large-scale agricultural research. You now have the capability of easily exploiting genomic information for enhancing your animal and plant crossing and breeding programs.
Selected Publications:
Kumari et al. performed somatic mutation profiling in gall bladder cancer samples. Lange et al. is a GWAS with follow-up for association with early-onset prostate cancer. Lian et al. used EpiTYPER in a study of renal cell carcinoma.
Pei et al. is a candidate genotyping study for association with breast cancer risk. Wang et al. is a candidate genotyping study for association with esophageal squamous cell carcinoma risk.
Dong et al. is a candidate genotyping study for association with pancreatic cancer risk. Cao et al. is a candidate genotyping study for association with idiopathic recurrent early pregnancy loss.
Chang et al. used EpiTYPER in a study of ethnic differences in susceptibility to type 2 diabetes mellitus.
MacIntyre et al. is a candidate genotyping study for association with air pollution and asthma risk.
Wang et al. is a candidate genotyping study for association with eczema.
Ruan et al. is a candidate genotyping study for association with childhood obesity.
Gong et al. is a candidate genotyping study for association with coronary artery disease.
Oka et al. used iPLEX for QTL mapping in a study of hybrid sterility in mice
Video Links:
https://www.youtube.com/watch?v=7TLz-nWChY8